Osiris Therapeutics

Vesselon Discovery Protects and Expands Drug Franchises

Retrieved on: 
Monday, May 22, 2023
Liposome, Tissue, Pancreatic cancer, Mode of action, Spencer Trask & Co., Myriad Genetics, Cell, IP, Therapeutic index, Malignancy, Genetics, Protein, Dicarboxylic acid, Publication, Patent, Risk, Peptide, Potyvirus, Neoplasm, Cytokine, Osiris Therapeutics, FDA, Therapy, Safety, Pharmaceutical industry, Vaccine, Medical imaging

GREENWICH, Conn., May 22, 2023 /PRNewswire/ -- In a major development, Vesselon has discovered how to protect a superior method of delivering drugs shown to be effective in more than 1,700 independent preclinical and clinician-sponsored human trials. Despite compelling evidence that the method improves the Therapeutic Index of numerous drugs in many indications, its promise has been ignored by the pharmaceutical industry because it has not been patentable, until now.

Key Points: 
  • Based on this discovery, the drug maker has filed patents on its TriForm™ lipid platform.
  • The on-site, in-vial mixing process instantly combines a therapeutic drug with the FDA-approved Vesselon lipid microsphere shown to have the same safety level as saline.
  • After mixing a standard dose, each vial contains approximately 10 billion lipid microspheres encapsulating the active drug, 50 trillion liposomes loaded with the active drug, as well as the freely circulating drug.
  • In addition to existing franchises, current and future pipeline drugs will also benefit from the Vesselon platform.

Terran Orbital Appoints James Black as Senior Vice President and General Counsel

Retrieved on: 
Tuesday, December 13, 2022
Technology, Engineering, Aerospace, Manufacturing, Military, Air, Defense, Transport, Other Technology, Other Defense, Hardware, Other Manufacturing, Government Technology, Satellite, Therapy, George Washington University, Hogan Lovells, Orbital Sciences Corporation, General counsel, Ultra Electronics, College of William & Mary, LLAP, Grumman, Osiris Therapeutics, College, NYSE, Assistant, ATK, Hogan, Orbital, Orbital Corporation, Senior, Multimedia, Osiris, Northrop, Lawyer, Northrop Grumman, James Madison University, Management, Communications satellite, Science, Anthropology

Terran Orbital Corporation (NYSE: LLAP ), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced the appointment of James Black as Senior Vice President and General Counsel.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP ), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced the appointment of James Black as Senior Vice President and General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20221207005919/en/
    Terran Orbital Appoints James Black as Senior Vice President and General Counsel (Image Credit: Terran Orbital Corporation)
    Marc Bell, Terran Orbitals Co-Founder, Chairman, and Chief Executive Officer commented, Welcoming Jim into the Terran Orbital family has been a privilege.
  • Prior to Terran Orbital, Jim served as Vice President and Deputy General Counsel of the North American division of UK defense company Ultra Electronics and Chief Legal Officer at Osiris Therapeutics.
  • Mr. Black also served as Director and Corporate Counsel at Northrop Grumman and Vice President and Deputy General Counsel at aerospace and defense company Orbital ATK.

Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer

Retrieved on: 
Friday, August 26, 2022
Security (finance), U.S. Securities and Exchange Commission, California Institute for Regenerative Medicine, CIRM, Therapy, Rice University, Regenerative medicine, Medicine, Osiris Therapeutics, Science, Duke University, Goal, Grant (money), American Institute, Biomedical engineering, GLOBE, American Institute for Medical and Biological Engineering, Leadership, Company, FDA, Doctor of Philosophy, Biological engineering, Investor, Private Securities Litigation Reform Act, Forward-looking statement, Columbia, Patient

SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer.

Key Points: 
  • SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer.
  • We believe her ability to develop great products, backed by strong science, and through efficient use of capital will create significant value for Aziyo.
  • Michelle LeRoux Williams, Ph.D., a fellow in the American Institute for Medical and Biological Engineering, is an internationally recognized expert in biologics and regenerative medicine.
  • I look forward to teaming up with some familiar faces to create some serious value at Aziyo, said Dr. Williams.

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

Retrieved on: 
Tuesday, August 9, 2022
People, Woman, Regeneration, U.S. Securities and Exchange Commission, Sustainability Accounting Standards Board, CEO, GLOBE, R, Forward-looking statement, Private Securities Litigation Reform Act, Regenerative medicine, Board, Medicine, Security (finance), Ernst & Young Entrepreneur of the Year Award, AATB, Patient, Therapy, Bone marrow, Company, Scientific Leadership, Skin, Biotechnology, Infection, Smith, World, Organization, Goal, Investor, National Marrow Donor Program, IPO, Osiris Therapeutics, California Institute for Regenerative Medicine, Heart block, Management, Pharmaceutical industry, Osiris, Transplant

SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.

Key Points: 
  • SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.
  • Since creating Aziyo in 2015, Randy and I have worked together to build a company where regenerative medicine is used to its full potential, said Kevin Rakin, co-founder and executive chairman.
  • Randy is a visionary leader with a track record of creating significant shareholder value in regenerative medicine.
  • The Board and I look forward to partnering with Randy as we make his vision for this company a reality.

Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

Retrieved on: 
Tuesday, June 21, 2022
R, Industry, Security (finance), Smith, FDA, Osiris, Regenerative medicine, Investor, California Institute for Regenerative Medicine, IPO, Ministry of Education (Malaysia), CEO, Company, ABH, U.S. Securities and Exchange Commission, Biotechnology, Bone marrow, Forward-looking statement, Private Securities Litigation Reform Act, Osiris Therapeutics, Regeneration, Acquisition, Nasdaq, Patient, National Marrow Donor Program, Therapy, Organization, GLOBE, Goal, Management, Pharmaceutical industry

SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-founder C. Randal (Randy) Mills, Ph.D., has been appointed interim president and CEO.

Key Points: 
  • SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-founder C. Randal (Randy) Mills, Ph.D., has been appointed interim president and CEO.
  • Randy and I thank Ron for his efforts and look forward to building upon the momentum that this impressive foundation affords.
  • Kevin and I have been very fortunate to have both led companies that successfully developed biosurgical innovations for patients in need, and in doing so, helped create significant value for shareholders, said Randy Mills, Ph.D., interim president and CEO.
  • Kevin Rakin, co-founder and executive chairman of Aziyo Biologics, is also a co-founder of HighCape Partners, an investment fund and affiliate of Aziyo.

$36.92 Billion Cell & Gene Therapy Market - Global Outlook & Forecasts, 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 1, 2022
Hospitals, FDA, Genetics, Stem Cells, Other Health, Managed Care, Radiology, General Health, Health, Oncology, Growth, Bristol Myers Squibb, USD, Therapy, Osiris Therapeutics, Smith & Nephew, Novartis Gene Therapies, Development, Cell, American Society for Cell Biology, Spark Therapeutics, CAGR, Society, Gene, Protest and strikes of the CGT union 2021, PRIME, Kite Pharma, FDA, Novartis, Gilead Sciences, Hospital, Mutation, Pharmaceutical industry, Organogenesis, Medicine

The "Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The advancement in the cell & gene therapy field and innovative technologies give the new era for biological therapeutics.
  • As per the American Society of Cell + Gene Therapy report in 2021, increasing the number of cellular and gene therapy products, application rate and products in clinical trials drive the market growth.
  • Europe: The increasing funding for cell and gene therapy drives the cell and gene therapy market growth consistently in Europe.

Aruvant Appoints Moya Daniels as Senior Vice President of Regulatory Affairs and Quality Assurance

Retrieved on: 
Monday, November 15, 2021
Mortality, GMP, Roivant Sciences, VP, Biomarker, SCD, Industry, Therapy, Regenerative medicine, MD, Osiris Therapeutics, Disease, GXP, Degenerative disease, SVP, Instagram, Aruval, Hypophosphatasia, Sickle cell disease, Survival, QA, GSK, FDA, CMC, Pharmaceutical industry

NEW YORK and BASEL, Switzerland, Nov. 15, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced the appointment of Moya M. Daniels as senior vice president (SVP) of regulatory affairs and quality assurance (QA), effective immediately.

Key Points: 
  • NEW YORK and BASEL, Switzerland, Nov. 15, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced the appointment of Moya M. Daniels as senior vice president (SVP) of regulatory affairs and quality assurance (QA), effective immediately.
  • Ms. Daniels brings over thirty years of regulatory, quality and clinical experience in the biopharmaceutical industry.
  • She served as SVP of regulatory affairs and global quality assurance at Orchard Therapeutics, where she led the company's chemistry, manufacturing and controls (CMC) regulatory and generic good practice (GXP) quality strategy.
  • Prior to Orchard, Ms. Daniels served as vice president (VP) of regulatory affairs and QA at Fate Therapeutics, Inc. and before that led global regulatory strategy, quality and clinical operations at Osiris Therapeutics.

Global Regenerative Medicine Market to 2024 - Dominated by Kite Pharma, Novartis, Vericel Corp, Integra LifeSciences, Wright Medical, MiMedx, Osiris Therapeutics, Stryker Corp, and Spark Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 18, 2019
Professional services, Consulting, Life sciences, Branches of biology, Articles, Emerging technologies, Vericel, Osiris Therapeutics, Novartis, Kite Pharma, Therapy, Gene therapy

The rising global incidence of cancer, increasing global aging population, and technological shifts in regenerative medicine such as CAR-T cell therapy are factors expected to drive market growth during the forecast period.

Key Points: 
  • The rising global incidence of cancer, increasing global aging population, and technological shifts in regenerative medicine such as CAR-T cell therapy are factors expected to drive market growth during the forecast period.
  • The major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).
  • By type, the regenerative medicine market is segmented into cell-based immunotherapy & cell therapy products, tissue-engineered products, and gene therapy products.
  • By application, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications.